Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients

Several recently published trials investigate novel therapies for relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real‐world setting, comprehensive data on patients treated in clinical routine are needed. We report outcomes for 736 R/R...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrysson, Sara, Eloranta, Sandra, Ekberg, Sara, Enblad, Gunilla, El‐Galaly, Tarec C., Sander, Birgitta, Sonnevi, Kristina, Andersson, Per‐Ola, Jerkeman, Mats, Smedby, Karin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545648/
https://www.ncbi.nlm.nih.gov/pubmed/35468219
http://dx.doi.org/10.1111/bjh.18197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545648/
https://www.ncbi.nlm.nih.gov/pubmed/35468219
http://dx.doi.org/10.1111/bjh.18197

Ejemplares similares